Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00773097 · ClinicalTrials.gov registry record · Phase 2
Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
A Phase 2 study of Risk for Colorectal Cancer, sponsored by Robert Schoen.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT00773097 is a Phase 2 study of Risk for Colorectal Cancer that has completed, run by Robert Schoen. The registered enrollment target is 46 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00773097, a Phase 2 study of Risk for Colorectal Cancer, has completed, sponsored by Robert Schoen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the immune response to MUC1 - poly-ICLC vaccine, an investigational or study vaccine. The MUC1 - poly-ICLC vaccine is being tested in persons with a history of advanced adenomatous polyps, the precursor to colorectal cancer. The MUC1 - poly-ICLC vaccine is being developed to prevent polyps from advancing into colon cancer and to prevent polyps from recurring. MUC1 is mucus that is normally present on the lining of the human colon. However, MUC1 is expressed in a larger amount and in a modified form on adenomatous polyps and colorectal cancer. These changes in MUC1 are thought to be part of the process of progression from adenomas toward cancer. The goal of a vaccine is to help the immune system in the body identify the changes in MUC1 that accompany the progression to cancer and eliminate the abnormal cells that make abnormal MUC1.
Conditions Studied
Interventions
- BIOLOGICAL MUC1 - Poly ICLC
Study Locations (1)
Pennsylvania
- Digestive Disorders Clinic - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00773097
The ClinicalTrials.gov registry entry for NCT00773097 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Robert Schoen, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Risk for Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which MUC1 - Poly ICLC is the first listed.
NCT00773097 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00773097 about?
NCT00773097 is a clinical study titled "Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma". The purpose of this study is to evaluate the immune response to MUC1 - poly-ICLC vaccine, an investigational or study vaccine. The MUC1 - poly-ICLC vaccine is being tested in persons with a history of advanced adenomatous polyps, the precursor to colorectal cancer. The MUC1 - poly-ICLC vaccine is be...
What is the current status of trial NCT00773097?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2008-10. Estimated completion is 2012-10.
What conditions does trial NCT00773097 study?
This clinical trial studies the following conditions: Risk for Colorectal Cancer.
What interventions are being tested in trial NCT00773097?
The interventions under investigation include: MUC1 - Poly ICLC (BIOLOGICAL).
Who is sponsoring clinical trial NCT00773097?
This trial is sponsored by Robert Schoen, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00773097 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.